Asianet Newsable on MSN
Sarepta hits fresh hurdle as court revives patent lawsuit with Regenxbio over muscular disorder therapy
While Sarepta’s gene therapy for the treatment of DMD called Elevidys was approved by the FDA in 2023, Regenxbio is ...
The Chosun Ilbo on MSN
Rising 'caregiving refugees' struggle in South Korea's aging society
Lee, 34 years old, from Suwon, Gyeonggi Province, watched her father collapse from a cerebral hemorrhage and undergo surgery in 2021. He spent six months in a university hospital and a rehabilitation ...
Eric Dane died on Thursday, Feb. 19, less than a year after he was diagnosed with ALS. The life expectancy for many is three to five years after diagnosis; however, some can live longer, according to ...
Dyne Therapeutics Inc. (NASDAQ: DYN) is one of the 13 hot stocks to buy with the highest upside potential. As of February 13, ...
Del-desiran (also known as AOC1001) is an antibody-oligonucleotide conjugate comprised of a DMPK small interfering RNA (siRNA ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results